Myelodysplastic Syndromes – Opportunity Analysis and Forecasts to 2028

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Myelodysplastic syndromes (MDS) are a relatively rare group of acquired clonal hematopoietic stem cell disorders characterized by dysfunctional hematopoiesis leading to cytopenias, with the potential to transform into acute myeloid leukemia (AML). DNA damage and mutations are the predominant factors contributing to MDS development and progression. As such, aging and the associated accumulation of mutations over time appear to be the most important risk factors for the disease. Clonal shifts in hematopoietic stem and progenitor cells due to mutations, cytogenetic alterations, and modified epigenetic marks can promote the expansion of abnormal, dysfunctional cells. In symptomatic MDS, these cellular changes manifest in pathophysiological changes including fatigue, bleeding and bruising, and increased risk of infection.
Therapeutic goals for patients with MDS differ depending on whether patients have lower or higher risk disease.
• How do the treatment goals for patients with HR-MDS and LR-MDS differ?
• How well are currently marketed therapies addressing the different needs of patients with higher and lower risk MDS?
With the launch of ten new pipeline agents expected between 2018 and 2028, GlobalData expects the MDS competitive landscape to undergo a significant transformation during the next decade
• What are the main R&D trends in the MDS market and which companies are leading the way?
• In what ways is clinical trial design for LR-MDS and HR-MDS changing and what aspects do KOLs believe should be addressed in the future?
• Are there major differences in the mechanisms of action used by therapies in late-stage versus early-stage clinical development?
Despite the recent burst in pipeline development for MDS, KOLs interviewed by GlobalData still noted a continued high level of unmet need for therapies targeting difficult-to-treat populations of patients.
• Which MDS patient populations have the greatest unmet need and why?
• How can the pharmaceutical industry address these needs?
• To what degree will the therapies under development fulfill these unmet needs?


Overview of MDS including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Topline MDS market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.

Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting MDS therapeutics sales in the 7MM.

Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global MDS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The greatest drivers of growth in the global MDS market include the launch of 10 new pipeline therapies during the forecast period and a growing number of incident cases in many 7MM countries due to an aging population.

The main barriers to growth in the MDS market include the launch of generics and biosimilars of major brands, including Vidaza (azacitidine), Revlimid (lenalidomide), and Aranesp (darbepoetin alfa), and the dominance of safe and effective generic and biosimilar products in the first-line setting for both LR-MDS and HR-MDS.

Among the late-stage pipeline products, KOLs were particularly enthusiastic about BMS’s recently approved anti-anemia agent, Reblozyl (luspatercept) for the treatment of LR-MDS and Aprea Therapeutics’ eprenetapopt plus azacitidine combination therapy for the treatment of TP53 mutant HR-MDS.

The most important unmet needs in the MDS disease space are the needs for novel therapeutics targeting difficult-to-treat patient groups including patients with HR-MDS and LR-MDS who fail the standard of care; LR-MDS patients with symptomatic neutropenia and thrombocytopenia; and more generally, HR-MDS patients, the majority of which are ineligible to safely receive HSCT, which is the only currently available curative therapy option.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

Develop business strategies by understanding the trends shaping and driving the global MDS therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MDS market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global MDS therapeutics market from 2018-2028.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

AbbVie Inc
Acceleron Pharma Inc
Agios Pharmaceuticals Inc
Amgen Inc
Aprea Therapeutics AB
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
Eisai Co Ltd
FibroGen Inc
Gamida Cell Ltd
Genentech Inc
Genzyme Corp
Geron Corp
Janssen-Cilag Ltd
Jazz Pharmaceuticals Plc
Johnson & Johnson
Kyowa Kirin Co Ltd
Nippon Shinyaku Co Ltd
Novartis AG
Otsuka Pharmaceutical Co Ltd
Onconova Therapeutics Inc
SymBio Pharmaceuticals Ltd
Pfizer Inc
Takeda Pharmaceutical Co Ltd

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Myelodysplastic Syndromes: Executive Summary

2.1 Moderate Growth Expected in MDS Market Between 2018 and 2028

2.2 Drug Developers Position Agents to Fill Key Vacancies in the Treatment Paradigms for Higher- and Lower-Risk MDS

2.3 Unmet Needs Persist in Difficult-to-Treat MDS Subgroups, Leaving Substantial Opportunity for Future Players

2.4 Current Late-Stage MDS Pipeline Offers a Range of New Options for Patients in the Front-Line and Later Treatment Settings

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Clinical Presentation and Diagnosis

4.3 Classification

4.3.1 WHO Classification Criteria for MDS

4.3.2 IPSS-R Classification

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for MDS (2018–2028)

5.5.1 Diagnosed Incident Cases of MDS

5.5.2 Age-Specific Diagnosed Incident Cases of MDS

5.5.3 Sex Specific Diagnosed Incident Cases of MDS

5.5.4 Diagnosed Incident Cases of MDS/MPN

5.5.5 Diagnosed Incident Cases of MDS by Subtype

5.5.6 Diagnosed Incident Cases of Primary/Secondary MDS

5.5.7 Diagnosed Incident Cases of MDS by Risk Group

5.5.8 Diagnosed Incident Cases of MDS by Mutations

5.5.9 Five-Year Diagnosed Prevalent Cases of MDS

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Current Treatment Options

6.1 Overview

6.1.1 HR-MDS

6.1.2 LR-MDS

6.2 Treatment Algorithm

6.2.1 HR-MDS

6.2.2 LR-MDS

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Novel Strategies to Address Standard of Care Failure

7.2.1 HMA Failure

7.2.2 ESA Failure

7.3 Therapeutic Options for LR-MDS Patients with Thrombocytopenia and Neutropenia

7.4 Safer Curative Therapy Options

8 R&D Strategies

8.1 Overview

8.1.1 Second-Generation HMAs to Combat Genericization of Vidaza and Dacogen

8.1.2 Novel Mechanisms to Promote Erythropoiesis in LR-MDS with Anemia

8.1.3 Front-Line Combination Therapy Regimens that Synergize with Azacitidine

8.1.4 Targeted Therapy Based on Mutational Status

8.1.5 Label Expansions of AML Therapeutics

8.2 Clinical Trial Design

8.2.1 HR-MDS

8.2.2 LR-MDS

8.2.3 Considerations for Future Clinical Trial Design

9 Pipeline Assessment

9.1 Overview

9.1.1 HR-MDS

9.1.2 LR-MDS

9.2 Innovative Early Stage Approaches

10 Pipeline Valuation Analysis

10.1 Clinical Benchmark of Key Pipeline Drugs

10.1.1 HR-MDS

10.1.2 LR-MDS

10.2 Commercial Benchmark of Key Pipeline Drugs

10.2.1 HR-MDS

10.2.2 LR-MDS

10.3 Competitive Assessment

10.3.1 HR-MDS

10.3.2 LR-MDS

10.4 Top-Line 10-Year Forecast

10.4.1 US

10.4.2 5EU

10.4.3 Japan

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.3.1 Forecasting Methodology

11.3.2 Diagnosed Patients

11.3.3 Percent Drug-Treated Patients

11.3.4 Drugs Included in Each Therapeutic Class

11.3.5 Launch and Patent Expiry Dates

11.3.6 General Pricing Assumptions

11.3.7 Individual Drug Assumptions

11.3.8 Generic and Biosimilar Erosion

11.3.9 Pricing of Pipeline Agents

11.3.10 Other General Assumptions

11.4 Primary Research – Key Opinion Leaders Interviewed for This Report

11.4.1 Key Opinion Leaders

11.4.2 Payers

11.5 Primary Research – Prescriber Survey

11.6 About the Authors

11.6.1 Analyst

11.6.2 Therapy Area Director

11.6.3 Epidemiologists

11.6.4 Epidemiology Reviewers

11.6.5 Global Director of Therapy Analysis and Epidemiology

11.6.6 Global Head and EVP of Healthcare Operations and Strategy

11.7 About GlobalData

11.8 Contact Us

11.9 Disclaimer

Frequently asked questions

Myelodysplastic Syndromes – Opportunity Analysis and Forecasts to 2028 thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Myelodysplastic Syndromes – Opportunity Analysis and Forecasts to 2028 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Oncology reports
Novartis AG - Digital Transformation Strategies
$1,495 | May 2023
Pfizer Inc - Digital Transformation Strategies
$1,495 | April 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Myelodysplastic Syndromes – Opportunity Analysis and Forecasts to 2028 in real time.

  • Access a live Myelodysplastic Syndromes – Opportunity Analysis and Forecasts to 2028 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.